REPLIMUNE GROUP, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares
REPLIMUNE GROUP, INC. (REPL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares of 12.49 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares · last filed 2026-08-14
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for the quarter ending 2026-06-30 was 12.49M shares, a 1.78% increase year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for the quarter ending 2026-03-31 was -142.51K shares, a 14112.98% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for the quarter ending 2025-12-31 was -304.79K shares.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for the quarter ending 2025-09-30 was -41.24K shares, a 154.96% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for fiscal 2026 was 11.79M shares, a 15.38% increase from fiscal 2025.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested, number of shares for fiscal 2025 was 10.21M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 12 month |
|---|---|---|---|---|
| 2026-06-30 | 12.49M shares 10-Q · filed 2026-08-14 | 12.35M shares derived: sum of 2 quarters · filed 2026-08-14 | 12.05M shares derived: sum of 3 quarters · filed 2026-08-14 | 12.00M shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -142.51K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | -447.30K shares derived: sum of 2 quarters · filed 2026-06-29 | -488.54K shares derived: sum of 3 quarters · filed 2026-06-29 | 11.79M shares 10-K · filed 2026-06-29 |
| 2025-12-31 | -304.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-03 | -346.03K shares derived: sum of 2 quarters · filed 2026-02-03 | 11.93M shares 10-Q · filed 2026-02-03 | 11.93M shares derived: sum of 4 quarters · filed 2026-02-03 |
| 2025-09-30 | -41.24K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06 | 12.23M shares 10-Q · filed 2025-11-06 | 12.23M shares derived: sum of 3 quarters · filed 2025-11-06 | 12.22M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 12.27M shares 10-Q · filed 2025-08-07 | 12.28M shares derived: sum of 2 quarters · filed 2025-08-07 | 12.26M shares derived: sum of 3 quarters · filed 2025-08-07 | 12.33M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 1.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | -17.21K shares derived: sum of 2 quarters · filed 2025-05-22 | 57.82K shares derived: sum of 3 quarters · filed 2025-05-22 | 10.21M shares 10-K · filed 2025-05-22 |
| 2024-12-31 | -18.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-12 | 56.81K shares derived: sum of 2 quarters · filed 2025-02-12 | 10.21M shares 10-Q · filed 2025-02-12 | |
| 2024-09-30 | 75.03K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | 10.23M shares 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | 10.16M shares 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | -322.32K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-08 | -234.24K shares derived: sum of 2 quarters · filed 2024-02-08 | 8.83M shares 10-Q · filed 2024-02-08 | |
| 2023-09-30 | 88.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-07 | 9.16M shares 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | 9.07M shares 10-Q · filed 2023-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |